Development of oligomeric prion-protein aggregates in a mouse model of prion disease

Journal of Pathology

Volumn 219, Issue 1, 2009, Pages 123-130

  Sasaki, Kensuke ^a   Minaki, Haruhiko ^a   Iwaki, Toru ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Creutzfeldt Jakob disease; Mouse model; Oligomer; Prion; Transimissible spongiform encephalopathy

Indexed keywords

MONOMER; OLIGOMER; PHOSPHOTUNGSTIC ACID; PRION PROTEIN; PROTEINASE K;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL MODEL; MOUSE; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SOLUBILITY;

ANIMALS; BLOTTING, WESTERN; BRAIN; BRAIN CHEMISTRY; CHROMATOGRAPHY, GEL; MICE; MICE, INBRED STRAINS; MODELS, ANIMAL; MOLECULAR WEIGHT; PEPTIDE HYDROLASES; PRION DISEASES; PROTEIN CONFORMATION; PRPC PROTEINS; PRPSC PROTEINS; TIME FACTORS;

EID: 68849128369     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2576     Document Type: Article

References (36)

1. Prusiner SB. Prion diseases and the BSE crisis. Science 1997;278:245-251.
2. Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, et al. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 1997;275:402-405.
3. Sc molecules with different conformations. Nat Med 1998;4:1157-1165.
4. Sc conformers induced by a synthetic peptide and several prion strains. J Virol 2004;78:2088-2099.
5. Safar JG, Geschwind MD, Deering C, Didorenko S, Sattavat M, Sanchez H, et al. Diagnosis of human prion disease. Proc Natl Acad Sci USA 2005;102:3501-3506.
6. Safar JG, Scott M, Monaghan J, Deering C, Didorenko S, Vergara J, et al. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol 2002;20:1147-1150.
7. Bellon A, Seyfert-Brandt W, Lang W, Baron H, Groner A, Vey M. Improved conformation-dependent immunoassay: suitability for human prion detection with enhanced sensitivity. J GenVirol 2003;84:1921-1925.
8. Cali I, Castellani R, Yuan J, Al-Shekhlee A, Cohen ML, Xiao X, et al. Classification of sporadic Creutzfeldt-Jakob disease revisited. Brain 2006;129:2266-2277.
9. Yuan J, Xiao X, McGeehan J, Dong Z, Cali I, Fujioka H, et al. Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains. J Biol Chem 2006;281:34848-34858.
10. Tcherkasskaya O, Davidson EA, Schmerr MJ, Orser CS. Conformational biosensor for diagnosis of prion diseases. Biotechnol Lett 2005;27:671-675.
11. Birkmann E, Schafer O, Weinmann N, Dumpitak C, Beekes M, Jackman R, et al. Detection of prion particles in samples of BSE and scrapie by fluorescence correlation spectroscopy without proteinase K digestion. Biol Chem 2006;387:95-102.
12. Vasan S, Mong PY, Grossman A. Interaction of prion protein with small highly structured RNAs: detection and characterization of PrP-oligomers. Neurochem Res 2006;31:629-637.
13. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860- 866.
14. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535- 539.
15. Kaylor J, Bodner N, Edridge S, Yamin G, Hong DP, Fink AL. Characterization of oligomeric intermediates in α-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F α-synuclein. J Mol Biol 2005;353:357-372.
16. Takahashi Y, Okamoto Y, Popiel HA, Fujikake N, Toda T, Kinjo M, et al. Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy. J Biol Chem 2007;282:24039-24048.
17. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002;418:291.
18. Singer SJ, Dewji NN. Evidence that Perutz's double-β-stranded subunit structure for β-amyloids also applies to their channel-forming structures in membranes. Proc Natl Acad Sci USA 2006;103:1546- 1550.
19. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003;26:267-298.
20. Wille H, Michelitsch MD, Guenebaut V, Supattapone S, Serban A, Cohen FE, et al. Structural studies of the scrapie prion protein by electron crystallography. Proc Natl Acad Sci USA 2002;99:3563-3568.
21. Yang S, Levine H, Onuchic JN, Cox DL. Structure of infectious prions: stabilization by domain swapping. FASEB J 2005;19:1778-1782.
22. Lin MC, Mirzabekov T, Kagan BL. Channel formation by a neurotoxic prion protein fragment. J Biol Chem 1997;272:44-47.
23. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, et al. The most infectious prion protein particles. Nature 2005;437:257-261.
24. Kazlauskaite J, Young A, Gardner CE, Macpherson JV, Venien-Bryan C, Pinheiro TJ. An unusual soluble β-turn-rich conformation of prion is involved in fibril formation and toxic to neuronal cells. Biochem Biophys Res Commun 2005;328:292-305.
25. Simoneau S, Rezaei H, Sales N, Kaiser-Schulz G, Lefebvre-Roque M, Vidal C, et al. In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog 2007;3:1175-1186.
26. Tateishi J, Ohta M, Koga M, Sato Y, Kuroiwa Y. Transmission of chronic spongiform encephalopathy with kuru plaques from humans to small rodents. Ann Neurol 1979;5:581-584.
27. Sasaki K, Doh-ura K, Ironside J, Mabbott N, Iwaki T. Clusterin expression in follicular dendritic cells associated with prion protein accumulation. J Pathol 2006;209:484-491.
28. Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001;358:171-180.
29. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-489.
30. Jimenez-Huete A, Lievens PM, Vidal R, Piccardo P, Ghetti B, Tagliavini F, et al. Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues. Am J Pathol 1998;153:1561-1572.
31. Minaki H, Sasaki K, Honda H, Iwaki T. Prion protein oligomers in Creutzfeldt-Jakob disease detected by gel-filtration centrifuge columns. Neuropathology 2009;DOI:10.1111/j.1440-1789.2009.01007.x.
32. Borchelt DR, Scott M, Taraboulos A, Stahl N, Prusiner SB. Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol 1990;110:743-752.
33. Pan T, Wong P, Chang B, Li C, Li R, Kang SC, et al. Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease. J Virol 2005;79:934-943.
34. Sc. Br Med Bull 2003;66:21-33.
35. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001;411:810-813.
36. Sc fraction. Biochemistry 2006;45:15710-15717.